Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.51 |
| ▸ | REN | P00797 | 1/20 | 0.44 |
| ▸ | NTSR1 | P30989 | 4/20 | 0.43 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30933096 | 0.93 | APLNR (0.51) | APLNRRENNTSR1NTSR2OPRM1 | |
| SCHEMBL30933095 | 0.93 | APLNR (0.54) | APLNRRENNTSR1OPRM1OPRK1 | |
| SCHEMBL29421949 | 0.92 | APLNR (0.49) | APLNRRENNTSR1NTSR2OPRD1 | |
| SCHEMBL30933156 | 0.92 | APLNR (0.53) | APLNRRENNTSR1OPRD1 | |
| SCHEMBL30170451 | 0.92 | APLNR (0.53) | APLNRRENNTSR1OPRD1 | |
| SCHEMBL30933143 | 0.92 | APLNR (0.53) | APLNRRENNTSR1OPRD1 | |
| SCHEMBL29904095 | 0.92 | APLNR (0.48) | APLNRRENNTSR1NTSR2OPRD1 | |
| SCHEMBL30933107 | 0.91 | APLNR (0.51) | APLNRRENOPRM1OPRK1OPRD1 | |
| SCHEMBL30933116 | 0.90 | APLNR (0.51) | APLNRRENOPRM1OPRK1OPRD1 | |
| SCHEMBL30933141 | 0.90 | APLNR (0.51) | APLNRRENOPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037415-B2 | Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient | YUYU PHARMA, INC. (KR) | 2024-07-16 | — | — | US | claimed |
| EP-4114430-A2 | TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS | YUYU Pharma, Inc. (KR) | 2023-01-11 | — | — | EP | claimed |
| EP-3974441-A1 | NOVEL PEPTIDE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | EYEBIO KOREA (KR) | 2022-03-30 | — | — | EP | claimed |
| US-12428446-B2 | Peptide compound or pharmaceutically acceptable salt thereof | EYEBIO KOREA (KR) | 2025-09-30 | — | — | US | disclosed |
| EP-4483959-A2 | NOVEL PEPTIDE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | EYEBIO KOREA (KR) | 2025-01-01 | — | — | EP | disclosed |
| EP-3974441-B1 | PEPTIDE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | EYEBIO KOREA (KR) | 2024-12-04 | — | — | EP | disclosed |
| US-20240352071-A1 | Novel Peptide Compound Or Pharmaceutically Acceptable Salt Thereof | EYEBIO KOREA (KR) | 2024-10-24 | — | — | US | disclosed |
| US-20240228538-A1 | Novel Peptide Compound Or Pharmaceutically Acceptable Salt Thereof | EYEBIO KOREA (KR) | 2024-07-11 | — | — | US | disclosed |
| EP-3974441-A1 | NOVEL PEPTIDE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | EYEBIO KOREA (KR) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428446-B2 | Peptide compound or pharmaceutically acceptable salt thereof | VIP, FURIN, IAPP | APLNR 201/4885REN 38/4885NTSR1 170/4885 |
| US-20240228538-A1 | Novel Peptide Compound Or Pharmaceutically Acceptable Salt Thereof | VIP, NPPA, NGLY1 | APLNR 228/4885REN 35/4885NTSR1 215/4885 |
| US-12037415-B2 | Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient | VIP, IAPP, NGLY1 | APLNR 334/4885REN 1013/4885NTSR1 1091/4885 |
| US-20240352071-A1 | Novel Peptide Compound Or Pharmaceutically Acceptable Salt Thereof | VIP, NPPA, NGLY1 | APLNR 228/4885REN 35/4885NTSR1 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.